Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized placebo-controlled trial of survodutide in adults with non-cirrhotic MASH/NASH and F2-F3 liver fibrosis
2024-513739-25-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2025
- Modality
- Peptides
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Survodutide with Placebo (2 arms). Planned start Apr 2025; status: authorised.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2024-513739-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513739-25-00.